These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1820192)

  • 21. Comparison of three types of reagents for detection of Bacteroides fragilis by direct immunofluorescence.
    Rokosz A; Meisel-Mikołajczyk F; Dzielska D
    Acta Microbiol Pol; 1986; 35(3-4):233-9. PubMed ID: 2436450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Properties of Bacteroides fragilis antigens with specificity B.
    Sawicka-Grzelak A; Meisel-Mikołajczyk F
    Acta Microbiol Pol; 1985; 34(1):47-53. PubMed ID: 2579527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
    Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition.
    Kasper DL
    J Infect Dis; 1976 Jan; 133(1):79-87. PubMed ID: 1451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Endotoxin production in members of the Bacteroides fragilis group in relation to colorectal cancer humans].
    Chmelar D; Vrtný J
    Klin Mikrobiol Infekc Lek; 2010 Jun; 16(3):97-102. PubMed ID: 20640988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenic characteristics of enterotoxigenic and nonenterotoxigenic isolates of Bacteroides fragilis.
    Myers LL; Shoop DS
    Am J Vet Res; 1987 Apr; 48(4):643-5. PubMed ID: 3109288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a direct fluorescent antibody staining method for rapid identification of members of the bacteroides fragilis group.
    DeGirolami PC; Mepani CP
    Am J Clin Pathol; 1981 Jul; 76(1):78-82. PubMed ID: 7020409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of pure or combined inocula of Escherichia coli and Bacteroides fragilis on the liver and related metabolism.
    Rink RD; Kaelin CR; Raque G; Trachtenberg LS; Fry DE
    Lab Invest; 1982 Mar; 46(3):282-7. PubMed ID: 7038296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Bacteroides fragilis, Bacteroides thetaiotaomicron, and Bacteroides ovatus in clinical specimens by immunofluorescence with a monoclonal antibody to B. fragilis lipopolysaccharide.
    Viljanen MK; Linko L; Lehtonen OP
    J Clin Microbiol; 1988 Mar; 26(3):448-52. PubMed ID: 3281973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of lipopolysaccharide and outer membrane of Bacteroides fragilis by an antibody-inhibition enzyme-linked immunosorbent assay in physiologic fluids and infected animals.
    Rissing JP; Buxton TB; Harris R; Moore W
    J Lab Clin Med; 1981 Nov; 98(5):784-94. PubMed ID: 7299246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenicity of the Bacteroides fragilis group.
    Brook I
    Ann Clin Lab Sci; 1989; 19(5):360-76. PubMed ID: 2679351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infection with Bacteroides fragilis: pathogenesis and immunoprophylaxis in an animal model.
    Kasper DL; Onderdonk AB
    Scand J Infect Dis Suppl; 1982; 31():28-33. PubMed ID: 6954635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological detection of Bacteroides fragilis in clinical samples.
    Patrick S; Stewart LD; Damani N; Wilson KG; Lutton DA; Larkin MJ; Poxton I; Brown R
    J Med Microbiol; 1995 Aug; 43(2):99-109. PubMed ID: 7629860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody response in thirteen patients with Bacteroides fragilis infections.
    Schwan A; Rydén AC
    Scand J Infect Dis; 1978; 10(3):213-8. PubMed ID: 362516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Bacteroides fragilis by co-agglutination, using a specific monoclonal antibody.
    Zhang G; Weintraub A
    Anaerobe; 1997 Oct; 3(5):295-300. PubMed ID: 16887604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis.
    Kasper DL; Onderdonk AB; Crabb J; Bartlett JG
    J Infect Dis; 1979 Nov; 140(5):724-31. PubMed ID: 528789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibody titer to Bacteroides fragilis is increased in Crohn disease patients with fistula development].
    Pietsch M; Brake BA; Schulz TF; Dierich MP
    Z Gastroenterol; 1986 May; 24(5):269-75. PubMed ID: 2425502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic diagnosis of Legionnaires' disease: cross-reactions with anaerobic and microaerophilic organisms and infections caused by them.
    Edelstein PH; McKinney RM; Meyer RD; Edelstein MA; Krause CJ; Finegold SM
    J Infect Dis; 1980 May; 141(5):652-5. PubMed ID: 6989933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid diagnosis of Bacteroides infections by indirect immunofluorescence assay of clinical specimens.
    Kasper DL; Fiddian AP; Tabaqchali S
    Lancet; 1979 Feb; 1(8110):239-42. PubMed ID: 84899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.